U.S. patent application number 16/192674 was filed with the patent office on 2019-06-27 for slow release pharmaceutical composition made of microparticles.
The applicant listed for this patent is Debiopharm Research & Manufacturing SA. Invention is credited to Marie-Anne BARDET, Catherine CURDY, Bertrand DUCREY, Patrick GARROUSTE, Frederic HEIMGARTNER, Eija LUNDSTROM, Herve PORCHET.
Application Number | 20190192423 16/192674 |
Document ID | / |
Family ID | 40032512 |
Filed Date | 2019-06-27 |
![](/patent/app/20190192423/US20190192423A1-20190627-D00001.png)
![](/patent/app/20190192423/US20190192423A1-20190627-D00002.png)
![](/patent/app/20190192423/US20190192423A1-20190627-D00003.png)
United States Patent
Application |
20190192423 |
Kind Code |
A1 |
DUCREY; Bertrand ; et
al. |
June 27, 2019 |
Slow Release Pharmaceutical Composition Made of Microparticles
Abstract
Pharmaceutical composition made of microparticles for the slow
release of an active substance at least during a period covering
the 6th month after injection of said composition, said composition
comprising a group of microparticles made of a copolymer of the
PLGA type which incorporate an active substance in the form of a
water insoluble peptide salt; said copolymer furthermore comprising
at least 75% of lactic acid and an inherent viscosity between 0.1
and 0.9 dl/g, as measured in chloroform at 25.degree. C. and at a
polymer concentration of 0.5 g/dL; said microparticles furthermore
having a size distribution defined as follows: --D (v,0.1) is
between 10 and 30 micrometers, --D (v,0.5) is between 30 and 70
micrometers, --D(v,0.9) is between 50 and 1 10 micrometers.
Inventors: |
DUCREY; Bertrand; (Martigny,
CH) ; GARROUSTE; Patrick; (Saxon, CH) ; CURDY;
Catherine; (Riehen, CH) ; BARDET; Marie-Anne;
(Maracon, CH) ; PORCHET; Herve; (Cugy, CH)
; LUNDSTROM; Eija; (Lutry, CH) ; HEIMGARTNER;
Frederic; (Marin-Epagnier, CH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Debiopharm Research & Manufacturing SA |
Martigny |
|
CH |
|
|
Family ID: |
40032512 |
Appl. No.: |
16/192674 |
Filed: |
November 15, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12601649 |
Apr 20, 2010 |
10166181 |
|
|
PCT/IB08/52241 |
Jun 6, 2008 |
|
|
|
16192674 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/34 20130101;
A61K 9/0019 20130101; A61K 9/19 20130101; A61P 35/00 20180101; A61P
5/06 20180101; A61K 9/1647 20130101; A61K 38/09 20130101 |
International
Class: |
A61K 9/00 20060101
A61K009/00; A61K 9/16 20060101 A61K009/16 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 6, 2007 |
EP |
07109767.9 |
Oct 27, 2007 |
IB |
PCT/IB2007/054372 |
Claims
1-14. (canceled)
15. A method of treating prostate cancer in a patient in need
thereof comprising administering to the patient a pharmaceutical
composition comprising microparticles comprising triptorelin
pamoate, wherein the microparticles are made of poly(D,L
lactide-co-glycolide) (PLGA), wherein the PLGA comprises at least
75% lactide, and wherein the triptorelin pamoate is released from
the pharmaceutical composition in an immediate amount within hours
following injection and then constantly released over a period of
at least 168 days.
16. The method of claim 15, wherein the composition is administered
once every 6 months to the patient.
17. The method of claim 15, wherein the composition comprises two
groups of microparticles.
18. The method of claim 17, wherein at least one of the two group
of microparticles is a group of microspheres.
19. The method of claim 18, wherein one group of microparticles is
microspheres and the second group of microparticles is
microgranules.
20. The method of claim 17, wherein the two groups of
microparticles are a first group of microgranules and a second
group of microgranules.
21. The method of claim 20, wherein the first group of
microgranules is a first formulation of microgranules comprising
approximately 20% (w/w) of triptorelin pamoate mixed with
approximately 80% (w/w) PLGA, wherein the PLGA in the first
formulation contains approximately 85% lactide and 15% glycolide
and the second group of microgranules is a second formulation of
microgranules comprising approximately 12% (w/w) triptorelin
pamoate mixed with approximately 88% (w/w) poly(D,L
lactide-co-glycolide) (PLGA), wherein the PLGA in the second
formulation contains approximately 75% lactide and 25%
glycolide.
22. The method of claim 21, wherein the first group of
microgranules and the second group of microgranules are mixed to
have a 50:50 dose ratio of triptorelin.
23. The method of claim 15, wherein the pharmaceutical composition
induces chemical castration in the patient over a six-month period
of time.
24. The method of claim 15, wherein the patient has advanced
prostate cancer.
25. A method of inducing chemical castration in a patient in need
thereof comprising administering to the patient a pharmaceutical
composition comprising microparticles comprising triptorelin
pamoate, wherein the microparticles are made of poly(D,L
lactide-co-glycolide) (PLGA), wherein the PLGA comprises at least
75% lactide, and wherein the triptorelin pamoate is released from
the pharmaceutical composition in an immediate amount within hours
following injection and then constantly released over a period of
at least 168 days.
26. The method of claim 25, wherein the composition is administered
once every 6 months to the patient.
27. The method of claim 25, wherein the composition comprises two
groups of microparticles.
28. The method of claim 27, wherein at least one of the two group
of microparticles is a group of microspheres.
29. The method of claim 28, wherein one group of microparticles is
microspheres and the second group of microparticles is
microgranules.
30. The method of claim 27, wherein the two groups of
microparticles are a first group of microgranules and a second
group of microparticles.
31. The method of claim 30, wherein the first group of
microgranules is a first formulation of microgranules comprising
approximately 20% (w/w) of triptorelin pamoate mixed with
approximately 80% (w/w) PLGA, wherein the PLGA in the first
formulation contains approximately 85% lactide and 15% glycolide
and the second group of microgranules is a second formulation of
microgranules comprising approximately 12% (w/w) triptorelin
pamoate mixed with approximately 88% (w/w) poly(D,L
lactide-co-glycolide) (PLGA), wherein the PLGA in the second
formulation contains approximately 75% lactide and 25%
glycolide.
32. The method of claim 31, wherein the first group of
microgranules and the second group of microgranules are mixed to
have a 50:50 dose ratio of triptorelin.
33. The method of claim 25, wherein the patient has advanced
prostate cancer.
Description
FIELD OF INVENTION
[0001] The invention relates to pharmaceutical compositions made of
microparticles which are used for the slow release of an active
substance.
[0002] It more precisely relates to such compositions which
comprise a copolymer of lactic and glycolic acid (PLGA)
incorporating, as active substance, a water insoluble peptide
salt.
STATE OF THE ART
[0003] Compositions as defined above are disclosed in Swiss patent
CH 679 207 A5.
Definitions
[0004] In the present text, the term "microparticle" has to be
understood as a solid object of any shape, e.g. microsphere or
microgranule, having a median diameter of less than 250
micrometers.
[0005] The expression D (v,0.5), also mentioned as "median
diameter", means that 50% of the microparticles have a diameter
which is less than the indicated value.
[0006] Hence, if D (v,0.5)=55 micrometers, 50% of the
microparticles have a diameter which is less than 55
micrometers.
[0007] In the same way, D (v,0.1) means that 10% of the
microparticles have a diameter which is less than the indicated
value and D (v,0.9) means that 90% of the microparticles have a
diameter which is less than the indicated value.
[0008] All above values are measured by laser diffraction.
[0009] The term "microgranule" refers to an object which is the
result of a milling operation on an elongated product such as an
extrudate.
[0010] The term PLGA XX/YY refers to a poly(D,L
lactide-co-glycolide), where XX represents the lactide content, and
YY represents the glycolide content. The ratio lactide/glycolide
being expressed in mol percent.
[0011] The term "month" refers to 28 days.
General Description of the Invention
[0012] The objective of the invention is to offer several
improvements with respect to the state of the art.
[0013] One of those improvements is to provide a continuous and
efficient slow release of the active substance during at least a
period covering the 6.sup.th month after injection of the
composition.
[0014] To this effect the invention concerns a pharmaceutical
composition made of microparticles for the slow release of an
active substance at least during a period covering the 6.sup.th
month after injection of said composition, said composition
comprising a group of microparticles made of a copolymer of the
PLGA type which incorporate an active substance in the form of a
water insoluble peptide salt; said copolymer furthermore comprising
at least 75% of lactic acid and an inherent viscosity between 0.1
and 0.9 dl/g, as measured in chloroform at 25.degree. C. and at a
polymer concentration of 0.5 g/dL; said microparticles furthermore
having a size distribution defined as follows: [0015] D (v,0.1) is
between 10 and 30 micrometers, [0016] D (v,0.5) is between 30 and
70 micrometers, [0017] D(v,0.9) is between 50 and 110
micrometers.
[0018] In a first embodiment, the composition consists of one
single group of microparticles. In that case the lactide content of
the PLGA is of at least 85% and the inherent viscosity is between
0.1 and 0.4 dl/g.
[0019] A release during at least 6 months can be obtained with the
composition of this first embodiment.
[0020] The microparticles may be microspheres or microgranules.
[0021] In a second embodiment, the composition comprises a group of
microparticles wherein the lactide content of the PLGA is of at
least 85% and the inherent viscosity is preferably between 0.5 and
0.9 dl/g and more preferably between 0.63 and 0.67 dl/g.
[0022] The microparticles may be microspheres or microgranules
[0023] The group of microparticles defined in the second embodiment
may advantageously be used for providing a slow and significant
release during at least a period starting from the 4.sup.th month
after injection of the composition until and including the 6.sup.th
month.
[0024] In a third embodiment, the pharmaceutical composition
furthermore comprises another group of microparticles made of a
copolymer of the PLGA type having a lactide content between 70% and
80% which incorporates said active substance.
[0025] Both groups of microparticles may be present in a dose ratio
(expressed in peptide content) close to 50:50.
[0026] The inherent viscosity of each group is between 0.5 and 0.9
dl/g.
[0027] Preferably the inherent viscosity of the other group is
between 0.60 and 0.70 dl/g and in particular 0.65 dl/g and the
inherent viscosity of the first group is the same as the one
defined in the second embodiment.
[0028] The microparticles of the other group may be microgranules
or microspheres.
[0029] Advantageously both groups of microparticles are
microgranules.
[0030] One group of microparticules is advantageously obtained by
mixing, in a solvent-free process, said PLGA with said water
insoluble peptide salt.
[0031] When two groups of microparticles are present, one group may
be used to provide a slow and significant release of the water
insoluble peptide salt during at 10 least the first three months
after injection of the composition while the other group is used
for a release starting from the 4.sup.th month.
[0032] In a preferred embodiment the active substance is a LHRH
agonist triptorelin (used as water insoluble salt such as the
pamoate salt thereof) which may be efficiently used in the
treatment of prostate cancer.
[0033] The LHRH agonist triptorelin is released in an important
immediate amount within hours following injection and then shows a
constant and significant release over a long period of at least 168
days, i.e. 6 months
DETAILED DESCRIPTION OF THE INVENTION
[0034] The invention is discussed below in a more detailed way with
examples, the first being illustrated by the following figure:
[0035] FIG. 1 shows triptorelin, LHRH agonist, serum levels
obtained with the pharmaceutical biodegradable composition of
example 1,
[0036] FIG. 2 shows triptorelin, LHRH agonist, serum levels
obtained with the pharmaceutical biodegradable composition of
example 3,
[0037] FIG. 3 shows triptorelin, LHRH agonist, serum levels
obtained with the pharmaceutical biodegradable composition of
example 4,
[0038] In the following examples the viscosity is expressed in dl/g
and is measured at a polymer concentration of 0.5 g/dl.
Example 1
[0039] A formulation of microgranules of triptorelin pamoate is
prepared with the following process.
[0040] Approximately 12% (w/w) of triptorelin pamoate is mixed with
approximately 88% (w/w) PLGA 75/25 having a viscosity of 0.65 dl/g,
at room temperature. The given mixture is duly homogenized,
subjected to progressive compression and simultaneously to a
progressive heating, before extrusion. The extrudate is cut into
pellets and ground at a temperature of about -100.degree. C. The
microgranules obtained after grinding are sieved below 180
micrometers. Their size distribution is defined as follows:
[0041] D (v,0.1)=23 micrometers
[0042] D (v,0.5)=55 micrometers
[0043] D (v,0.9)=99 micrometers
[0044] A formulation of microspheres of triptorelin pamoate and
PLGA 85/15 having an inherent viscosity of 0.68 dl/g is prepared as
follows:
[0045] Aqueous phase is prepared by mixing, under magnetic
stirring, at a temperature of 40.degree. C., 240 g of polyvinyl
alcohol and 11760 g of purified water. In parallel, the organic
phase is prepared by total dissolution of 12 g of polymer 85/15
poly(D,L lactide-co-glycolide) (PLGA) in 45 g of ethyl acetate
under magnetic stirring.
[0046] 3000 mg of triptorelin pamoate are suspended in 30 g of
ethyl acetate and placed under magnetic stirring. This solution is
incorporated to the organic phase previously prepared. The organic
phase is then introduced in a homogenisation chamber simultaneously
with the said aqueous phase. Both phases are mixed in order to
obtain an emulsion and the extraction of the solvent from the
organic phase and to isolate a suspension of microspheres.
[0047] Finally the formulation of microspheres is recovered by
filtration and dried by lyophilization.
[0048] The microspheres have a size distribution defined as
follows:
[0049] D (v,0.1)=15.6 micrometers
[0050] D (v,0.5)=33.4 micrometers
[0051] D (v,0.9)=60.8 micrometers
[0052] The formulation of microspheres and the formulation of
microgranules are mixed in a vial in order to have a 50:50 dose
ratio of each formulation. The mixture is suspended in an
appropriate aqueous medium, lyophilised and sterilized by gamma
irradiation.
[0053] The purity measured on the obtained pharmaceutical
biodegradable composition is 98.3% and the burst evaluated in vitro
(in a phosphate buffer pH 7.4) over a 6 hours period is 22.1%.
[0054] In this example, the obtained pharmaceutical formulation is
tested in vivo and the animal model is the rat. The formulation as
described above is suspended in water for injection and is
administered at a concentration dose of 18 mg/kg to 6 rats.
[0055] The LHRH agonist triptorelin of said pharmaceutical
biodegradable composition is released in an important immediate
amount within hours following injection and then shows a constant
and significant release over a long period of at least 168 days,
i.e. 6 months.
Example 2
[0056] A formulation of microgranules of triptorelin pamoate is
prepared as described in example 1.
[0057] A formulation of microspheres of triptorelin pamoate is
prepared as described in example 1 with PLGA 90/10 having an
inherent viscosity of 0.7 dl/g.
[0058] The microspheres have a size distribution defined as
follows:
[0059] D (v,0.1)=17.6 micrometers
[0060] D (v,0.5)=39.9 micrometers
[0061] D (v,0.9)=84.2 micrometers
[0062] The formulation of microspheres and the formulation of
microgranules are mixed in a vial in order to have a 50:50 dose
ratio of each formulation. The mixture is suspended in an
appropriate aqueous medium, lyophilised and sterilized by gamma
irradiation.
[0063] The purity measured on the obtained pharmaceutical
biodegradable composition is 98.3% and the burst evaluated in vitro
(in a phosphate buffer pH 7.4) over a 6 hours period is 19.4%.
[0064] The LHRH agonist triptorelin of said pharmaceutical
biodegradable composition is released in an important immediate
amount within hours following injection and then shows a constant
and significant release over a long period of at least 168 days,
i.e. 6 months.
Example 3
[0065] A formulation of microgranules of triptorelin pamoate is
prepared as described in example 1.
[0066] Another formulation of microgranules is prepared as
described in example 1 with PLGA 85/15 having an inherent viscosity
of 0.66 dl/g.
[0067] Approximately 20% (w/w) of triptorelin pamoate is mixed with
approximately 80% (w/w) PLGA 85/15 at room temperature. The given
mixture is duly homogenized, subjected to progressive compression
and simultaneously to a progressive heating, before extrusion. The
extrudate is cut into pellets and ground at a temperature of about
-100.degree. C. The microgranules obtained after grinding are
sieved below 180 micrometers. Their size distribution is defined as
follows:
[0068] D (v,0.1)=20.5 micrometers
[0069] D (v,0.5)=51.7 micrometers
[0070] D (v,0.9)=96.9 micrometers
[0071] The 2 formulations of microgranules are mixed in a vial in
order to have a 50:50 dose ratio of each formulation. The mixture
is suspended in an appropriate aqueous medium, lyophilised and
sterilized by gamma irradiation.
[0072] The purity measured on the obtained pharmaceutical
biodegradable composition is 98.8% and the burst evaluated in vitro
(in a phosphate buffer pH 7.4) over a 6 hours period is 45.0%.
[0073] In this example, the obtained pharmaceutical formulation is
tested in vivo and the animal model is the rat. The formulation as
described above is suspended in water for injection and is
administered at a concentration dose of 18 mg/kg to 6 rats.
[0074] The LHRH agonist triptorelin of said pharmaceutical
biodegradable composition is released in an important immediate
amount within hours following injection and then shows a constant
and significant release over a long period of at least 168 days,
i.e. 6 months (see FIG. 2).
Example 4
[0075] A formulation of microspheres of triptorelin pamoate and
PLGA 95/5 having an inherent viscosity of 0.18 dl/g is prepared as
follows:
[0076] Aqueous phase is prepared by mixing, under magnetic
stirring, at a temperature of 40.degree. C., 800 g of polyvinyl
alcohol and 40 L of purified water. In parallel, the organic phase
is prepared by total dissolution of 80 g of PLGA 95/5 in 334 g of
isopropyl acetate under magnetic stirring.
[0077] 20 g of triptorelin pamoate are suspended in 100 g of
isopropyl acetate and placed under magnetic stirring. This solution
is incorporated to the organic phase previously prepared. The
organic phase is then introduced in a homogenisation chamber
simultaneously with the said aqueous phase. Both phases are mixed
in order to obtain an emulsion and the extraction of the solvent
from the organic phase and to isolate a suspension of
microspheres.
[0078] Finally the formulation of microspheres is recovered by
filtration and dried by lyophilization.
[0079] The microspheres have a size distribution defined as
follows:
[0080] D (v,0.1)=17.8 micrometers
[0081] D (v,0.5)=37.1 micrometers
[0082] D (v,0.9)=74.8 micrometers
[0083] This formulation of microspheres is suspended in an
appropriate aqueous medium, lyophilised and sterilized by gamma
irradiation.
[0084] The purity measured on the obtained pharmaceutical
biodegradable composition is 99.2% and the burst evaluated in vitro
(in a phosphate buffer pH 7.4) over a 6 hours period is 10.9%.
[0085] In this example, the obtained pharmaceutical formulation is
tested in vivo and the animal model is the rat. The formulation as
described above is suspended in water for injection and is
administered at a concentration dose of 18 mg/kg to 6 rats.
[0086] The LHRH agonist triptorelin of said pharmaceutical
biodegradable composition is released in an important immediate
amount within hours following injection and then shows a constant
and significant release over a long period of at least 168 days,
i.e. 6 months (see FIG. 3).
Example 5
[0087] In order to increase patients' compliance and convenience
the inventors also developed a formulation as defined in previous
example 3 which allows one injection every 6 Months (24 Weeks). The
study discussed in this example 10 investigated the efficacy and
safety of this formulation after 2 consecutive intramuscular
injections of triptorelin pamoate 22.5 mg in 120 patients with
advanced prostate cancer. Four-weekly testosterone assessments were
performed over 48 weeks.
[0088] Serum testosterone concentrations fell to castrate levels
(51.735 nmol/L) in 97.5% of the patients on D29, and 93% of the
patients maintained castration from Week 8 to 48. Five out of 8
patients who escaped castration had only an isolated testosterone
breakthrough without rising PSA (Prostate Specific Antigen),
indicating maintained efficacy. Only one of these isolated
breakthroughs was a true "acute-on-chronic" phenomenon after the
second injection.
[0089] The median relative decreases in PSA from baseline were
96.9% at Week 24, and 96.4% at Week 48, when 80.9% of patients had
a normal PSA.
[0090] The type and incidence of AEs (Adverse Events) were
comparable with those observed with the registered triptorelin
formulations. As with other GnRH agonists, the most frequent drug
related AEs were hot flushes (71.7% of patients). The study drug
was very well tolerated locally.
[0091] The study discussed above shows that Triptorelin 6-Month
formulation is efficacious and safe in inducing chemical castration
in patients with advanced prostate cancer. This new convenient
formulation requires only 1 injection every 24 weeks, and shows
comparable efficacy and safety with the marketed 1- and 3-Month
formulations.
* * * * *